1
|
Key Words
- Adolescents
- Adolescents, Male
- Age Factors
- Biology
- Blood Coagulation Effects
- Clinical Research
- Contraception
- Contraceptive Agents, Estrogen--administraction and dosage
- Contraceptive Agents, Estrogen--side effects
- Contraceptive Agents, Estrogen--therapeutic use
- Contraceptive Agents, Female--administraction and dosage
- Contraceptive Agents, Female--side effects
- Contraceptive Agents, Female--therapeutic use
- Contraceptive Agents, Progestin--administraction and dosage
- Contraceptive Agents, Progestin--side effects
- Contraceptive Agents, Progestin--therapeutic use
- Contraceptive Agents--administraction and dosage
- Contraceptive Agents--side effects
- Contraceptive Agents--therapeutic use
- Contraceptive Methods--administraction and dosage
- Contraceptive Methods--side effects
- Contraceptive Methods--therapeutic use
- Demographic Factors
- Family Planning
- Hematological Effects
- Hemic System
- Lynestrenol--administraction and dosage
- Lynestrenol--side effects
- Lynestrenol--therapeutic use
- Mestranol--administraction and dosage
- Mestranol--side effects
- Mestranol--therapeutic use
- Oral Contraceptives, Combined
- Oral Contraceptives--administraction and dosage
- Oral Contraceptives--side effects
- Oral Contraceptives--therapeutic use
- Physiology
- Population
- Population Characteristics
- Research Methodology
- Youth
Collapse
|
2
|
Kistner RW. Newer synthetic progestins for the treatment of endometriosis. Prog Gynecol 2002; 5:283-302. [PMID: 12332429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
|
3
|
Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37:746-54. [PMID: 9366821 DOI: 10.1016/s0190-9622(97)70112-9] [Citation(s) in RCA: 150] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND An excess of androgen is believed to contribute to development of acne in some patients. Because oral contraceptives (OCs) may reduce the active androgen level, hormonal therapy with OCs has been used successfully to treat patients with acne, although this treatment has previously not been studied in placebo-controlled trials. OBJECTIVE Our purpose was to evaluate the efficacy of a triphasic, combination OC (ORTHO TRI-CYCLEN [Ortho-McNeil Pharmaceutical, Raritan, N.J.], norgestimate/ethinyl estradiol) compared with placebo in the treatment of moderate acne vulgaris. METHODS Two hundred fifty-seven healthy female subjects, 15 to 49 years of age with moderate acne vulgaris, were enrolled in a multicenter, randomized, double-blind, placebo-controlled clinical trial. Each month for 6 months, subjects received either 3 consecutive weeks of the OC (i.e., tablets containing a fixed dose of ethinyl estradiol [0.035 mg] and increasing doses of norgestimate [0.180 mg, 0.215 mg, 0.250 mg]) followed by 7 days of inactive drug or placebo (color-matched tablets). Efficacy was assessed by facial acne lesion counts, an investigator's global assessment, a subject's self-assessment, and an analysis of within-cycle variation (cycle 6) in lesion counts. RESULTS Of the 160 subjects in whom efficacy could be evaluated, the OC group showed a statistically significantly greater improvement than the placebo group for all primary efficacy measures. The mean decrease in inflammatory lesion count from baseline to cycle 6 was 11.8 (62.0%) versus 7.6 (38.6%) (p = 0.0001), and the mean decrease in total lesion count was 29.1 (53.1%) versus 14.1 (26.8%) (p = 0.0001) in the OC and placebo groups, respectively. In the investigator's global assessment, 93.7% of the active treatment group versus 65.4% of the placebo group were rated as improved at the end of the study (p < 0.001). Six of the seven secondary efficacy measures (total comedones, open comedones, closed comedones, papules, pustules, and the subject's self-assessment of study treatment) were also significantly more favorable in the OC group compared with the placebo group. CONCLUSION An OC containing 0.035 mg of ethinyl estradiol combined with the triphasic regimen of norgestimate is a safe and effective treatment of moderate acne vulgaris in women with no known contraindication to OC therapy.
Collapse
Affiliation(s)
- A W Lucky
- Dermatology Research Associates, Inc., Cincinnati, OH 45230, USA
| | | | | | | | | | | |
Collapse
|
4
|
Abstract
Forty-three homozygous (SS) female sickle cell anemic patients with a history of at least one painful crisis per month and desiring a reversible contraceptive were administered DMPA/3 months or Microgynon monthly. A third group of 16 surgically sterilized patients served as control. Patients were followed for 1 year to assess possible effects of the contraceptives on the patients' painful crises. No changes were observed in any of the groups in the hematological parameters. At the end of the study, 70% of the patients receiving DMPA were pain-free and only 16% of those still reporting painful crises rated them as intense. Patients receiving Microgynon also had an amelioration of the painful crises, although at a lower rate; after 12 months, 45.5% still experienced some crises. Although less marked than in the other groups, 50.5% of the control patients also reported an improvement of their painful crisis, which may be a result of closer medical care.
Collapse
Affiliation(s)
- M de Abood
- Hematology Section, Social Security Hospital, Madrid
| | | | | | | | | |
Collapse
|
5
|
Castelo-Branco C, Martínez de Osaba MJ, Pons F, Fortuny A. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. Metabolism 1997; 46:437-40. [PMID: 9109850 DOI: 10.1016/s0026-0495(97)90062-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
To evaluate the usefulness of D-Trp-6-luteinizing hormone-releasing hormone (LHRH) (triptorelin), a gonadotropin-releasing hormone (GnRH) analog (GnRHa), plus an oral contraceptive (OC) in the treatment of severe hirsutism, a total of 48 women between 19 and 35 years of age suffering from polycystic ovary syndrome (PCOS) with severe hirsutism were studied. Hyperandrogenism of adrenal origin was excluded in all subjects. Twenty-three patients received 3.75 mg D-Trp-6-LHRH intramuscularly monthly for 1 year plus an OC containing 30 micrograms ethinyl-estradiol and 150 micrograms desogestrel. A second group of 25 subjects received an OC containing 35 micrograms ethinyl-estradiol and 2 mg cyproterone acetate (CPA). Immediately before and after months 6 and 12 of therapy, bone mineral density (BMD) and Ferriman-Gallwey scores were evaluated and follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), prolactin (PRL), testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS), 17-OH-progesterone (17-OHP), and sex hormone-binding globulin (SHBG) were determined. After 1 year of follow-up study, the combination of a GnRHa plus OC resulted in a decrease of hirsutism similar to that observed in the CPA group (41.9% v 40.5%) and in a suppression of gonadotropins and ovarian steroids in all treated women, without significant changes in bone density. The GnRHa-OC combination can potentially be used in the treatment of hirsutism and hyperandrogenism.
Collapse
Affiliation(s)
- C Castelo-Branco
- Department of Gynaecology and Obstetrics, Hospital Clínic i Provincial, Barcelona, Spain
| | | | | | | |
Collapse
|
6
|
Said S, Sadek W, Rocca M, Koetsawang S, Kirwat O, Piya-Anant M, Dusitsin N, Sethavanich S, Affandi B, Hadisaputra W, Kazi A, Ramos RM, d'Arcangues C, Belsey EM, Noonan E, Olayinka I, Pinol A. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Hum Reprod 1996; 11 Suppl 2:1-13. [PMID: 8982739 DOI: 10.1093/humrep/11.suppl_2.1] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
A placebo-controlled randomized clinical trial was conducted in six centres to compare the effects of a 14 day treatment with either 50 micrograms ethinyl oestradiol daily or 2.5 mg oestrone sulphate daily, on depot medroxyprogesterone acetate (DMPA)-induced prolonged bleeding. Out of 1035 women admitted to the study, 278 requested treatment and were given ethinyl oestradiol (n = 90), oestrone sulphate (n = 91) or placebo (n = 97). Ethinyl oestradiol was successful in stopping the bleeding episode in 93% of cases, compared with oestrone sulphate and placebo which had success rates of 76 and 74% respectively. However, the relative advantage of ethinyl oestradiol was marginal, with an average reduction of 1 bleeding day and 3 spotting days compared with the other two groups. Immediately after treatment, women given ethinyl oestradiol had less bleeding but a more unpredictable pattern than the other two groups. In the long term, there were no differences between the bleeding patterns or the discontinuation rates for any reason in the three groups, and the most important single reason for discontinuation in those groups remained 'menstrual problems'. In summary, the study showed that treatment of DMPA-induced prolonged bleeding with ethinyl oestradiol had a limited short-term effect but no beneficial effect on the acceptability of DMPA as a contraceptive method. Treatment with oestrone sulphate was no different from placebo.
Collapse
Affiliation(s)
- S Said
- Department of Obstetrics and Gynecology, Shatby Maternity Hospital, Alexandria, Egypt
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
A clinical study was conducted to assess the effects of oestrogen in controlling increased endometrial bleeding problems in the first year of Norplant use. Three treatment groups were studied: (i) 50 micrograms ethinyl oestradiol (EE); (ii) a combined pill containing 30 micrograms EE and 150 micrograms levonorgestrel (LNG); and (iii) placebo. Based on menstrual diary records, women with prolonged, frequent or irregular bleeding, as defined by World Health Organization criteria, were randomly allocated to one treatment for 21 days. A first endometrial biopsy was taken before commencing treatment and a second biopsy at either day 14 or 21 of treatment. Following treatment, all subjects kept a menstrual diary card for 90 days. In this preliminary study, 48 subjects had completed the full 90 day post-treatment record. Within 21 days of EE treatment, the number of bleeding/spotting days was reduced significantly (P < 0.02). In the 90 days following treatment, the administration of EE and EE + LNG significantly decreased the number of bleeding/spotting days (P < 0.05). There was no reduction in the number of bleeding/spotting episodes in the EE and EE + LNG groups, but the length of each bleeding/spotting episode was significantly shorter (P < 0.05). Histopathological findings of endometrium on day 0 revealed consistent progestogenic effects, and there was no apparent change in response by day 14 or 21 of EE or EE + LNG treatment. The results of this study confirm the clinical effectiveness of EE and EE + LNG for the treatment of irregular, frequent and prolonged bleeding in Norplant users.
Collapse
Affiliation(s)
- J Witjaksono
- Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Indonesia, Indonesia
| | | | | | | |
Collapse
|
8
|
Abstract
Norplant, a systemic contraceptive, has been used extensively throughout the world. A major problem for consumers utilizing Norplant has been irregular, unpredictable uterine bleeding or spotting. This study seeks to determine whether or not an appropriate treatment could be found that will reduce the incidence of spotting and bleeding. Both a pilot study and an interim report of a multi-center trial utilizing ethinyl estradiol 20 micrograms for 10 days, versus Ibuprofen 800 mg three times a day for 5 days, versus placebo is reported. Based on the interim analysis of the multi-center trial, there is a reduction in the mean number of spotting days with one of the three treatments compared to the other two treatments (p = 0.044). There was no difference in the number of bleeding days between treatment regimen. It appears from a review of the literature that both oestrogen, progesterone, and non-steriodal anti-inflammatory agents may reduce the number of bleeding days or inhibit acutely the bleeding in women utilizing Norplant. The completion of this randomized multi-center trial will hopefully give us further insight into an effective treatment for controlling the irregular bleeding and/or spotting that occurs in Norplant users.
Collapse
Affiliation(s)
- D F Archer
- Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, USA
| | | | | |
Collapse
|
9
|
Abstract
Fifty-one hirsute women were randomly treated for nine months with ethinyl estradiol 35 ug plus norethindrone 0.4 mg or 30 ug ethinyl estradiol plus 1.5 mg norethindrone acetate if they needed contraception or spironolactone 200 mg daily if they did not. Metabolic evaluations in response to therapy demonstrated triglyceride elevations with the two oral contraceptives but not with spironolactone. While systolic blood pressure was lower with spironolactone, fasting insulin levels were higher as opposed to either low-dose oral contraceptive preparation. Ethinyl estradiol 30 ug plus 1.5 mg norethindrone acetate lowered 3-alpha-diol glucuronide levels, yet ethinyl estradiol 35 ug plus norethindrone 0.4 mg and spironolactone were more effective in lowering Ferriman-Gallwey Scores. Treatment strategies for hirsute women need to consider metabolic consequences as well as efficacy.
Collapse
Affiliation(s)
- R A Wild
- Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City 73190
| | | | | | | |
Collapse
|
10
|
Sobbrio GA, Granata A, D'Arrigo F, Arena D, Panacea A, Trimarchi F, Granese D, Pullè C. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation. Acta Eur Fertil 1990; 21:139-41. [PMID: 2149912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In order to evaluate the clinical and endocrinological efficacy of two low-dose oral contraceptives (OC) containing 30 micrograms Ethinylestradiol (EE) and 150 micrograms Desogestrel (DG) and 75 micrograms Gestodene (GD), respectively, an open randomized study was carried out in 34 young hirsute women, matched for body mass index and age. All of them met endocrine and ultrasonic criteria for Micropolycystic Ovary Syndrome (MPCO). The participants were randomly assigned to one of two pill groups (each of 17). The serum values for Total Testosterone (TT), Free Testosterone (FT), Androstenedione (A), Dehydroepiandrosterone (DHEA), Dehydroepiandrosterone Sulphate (DHEAS), 17-Hydroxyprogesterone (17Pg), Sex Hormone Binding Globulin (SHBG), Ceruloplasmin (CP), as well as Ferriman-Gallwey Index (FGI) and Free Androgen Index (FAI) were evaluated prior to and after EE-DG and EE-GD 6 cycle treatment. A significant decrease in TT, FT, A, 17Pg, DHEA, DHEAS, FGI, FAI was observed, SHRG and CP increased significantly. There were no significant differences between the two OC. Our results seem to indicate that both OC are equipotent as far as their pharmacological profile and residual androgenic activity are concerned. Therefore, these OC may represent a highly effective and suitable alternative to the treatment of hyperandrogenism related to MPCO.
Collapse
Affiliation(s)
- G A Sobbrio
- Instit. of Clinica Medica I, University of Messina, School of Medicine, Italy
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Falk RJ, Mullin BR. Exacerbation of adenomyosis symptomatology by estrogen-progestin therapy: a case report and histopathological observations. Int J Fertil 1989; 34:386-9. [PMID: 2574708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The present case report illustrates the hormonal sensitivity of adenomyosis. Administration of an estrogen-progestin combination for what was felt to be symptomatic endometriosis resulted in exacerbation of symptoms and growth of adenomyomas. Histopathologic examination of the hysterectomy specimen revealed a pattern of decidualization previously unreported, but consistent with current theories of experimental in vivo and in vitro decidua formation.
Collapse
Affiliation(s)
- R J Falk
- Department of Pathology, Columbia Hospital for Women Medical Center, Washington, D.C
| | | |
Collapse
|
12
|
Kasa M, Torok L. [Treatment of acne with an antiandrogen containing contraceptive (Diane 35)]. Borgyogy Venerol Sz 1988; 64:125-30. [PMID: 12282288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
|
13
|
Ruutiainen K. The effect of an oral contraceptive containing ethinylestradiol and desogestrel on hair growth and hormonal parameters of hirsute women. Int J Gynaecol Obstet 1986; 24:361-8. [PMID: 2880770 DOI: 10.1016/0020-7292(86)90156-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A group of 22 hirsute women was treated with a combination of 0.030 mg of ethinylestradiol and 0.150 mg of desogestrel (EE-DG) for 6 or 12 months. After 6 months the hair growth was decreased in 17 patients. There was a significant decrease in testosterone/sex hormone binding globulin (T/SHBG) ratio and serum dehydroepiandrosterone sulphate (DHEAS) levels. The changes in the hirsutism and the T/SHBG ratio showed correlation (rho 0.36, P less than 0.05). The patient groups with the best and the poorest clinical response differed in terms of summed changes in the T/SHBG ratio and DHEAS. These findings suggest that the therapeutic effect of the EE-DG is based on combined changes in the related hormone levels.
Collapse
|
14
|
Falsetti L, Dordoni D, Gastaldi C, Gastaldi A. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome. Acta Eur Fertil 1986; 17:19-25. [PMID: 2941960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The authors treated 28 patients with polycystic ovary syndrome (PCOS) with the new preparation SH B 209 AE consisting of 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate (EE + CPA) throughout 12 months. From the analysis of the endocrine and clinical modifications induced by the drug along with the negligible incidence of side effects the conclusion can be drawn that this new estro-progestational association is indicated in the therapy of PCOS.
Collapse
|
15
|
Crona N, Silfverstolpe G, Samsioe G. Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol. Contraception 1984; 29:261-70. [PMID: 6234148 DOI: 10.1016/s0010-7824(84)80006-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Twenty women, oophorectomized as part of the surgical treatment for cervical carcinoma in either clinical stage IB or IIA but otherwise healthy, participated in the study. After a period of six weeks without hormonal treatment, ten of them were given 150 micrograms desogestrel (DG) daily for three weeks followed by 150 micrograms DG + 30 micrograms ethinyl estradiol (EE) for six weeks and, finally, 30 micrograms EE alone for three weeks. The remaining ten women were given 150 micrograms levonorgestrel (NORG) and EE in a similar regimen. Before treatment and after each period of treatment, apo-lipoprotein AI and sex-hormone-binding globulin (SHBG) were assayed in serum. Both progestins decreased apo-AI and SHBG when given alone, thereby indicating an "androgenic" influence. In combination with EE, however, DG seems to be less "anti-oestrogenic" than NORG, as judged from the higher apo-AI and SHBG values after the combination DG + EE compared to those after NORG + EE.
Collapse
|
16
|
Abstract
In summary, the diagnostic tools are now available to ascertain whether elevated levels of androgens underlie some cases of acne vulgaris. Awareness of androgen excess as a contributing factor in acne may help to identify patients who would benefit from endocrine evaluation and, possibly, from hormonal therapy.
Collapse
|
17
|
Cunningham JR, Gidwani GP, Gupta MS, Duchesneau PM, Schumacher OP. Prolactin-secreting pituitary adenoma: occurrence following prenatal exposure to diethylstilbestrol. Cleve Clin Q 1982; 49:249-54. [PMID: 7168914 DOI: 10.3949/ccjm.49.4.249] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
18
|
Stevenson JC, Abeyasekera G, Hillyard CJ, Phang KG, MacIntyre I, Campbell S, Townsend PT, Young O, Whitehead MI. Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens. Lancet 1981; 1:693-5. [PMID: 6110915 DOI: 10.1016/s0140-6736(81)91973-5] [Citation(s) in RCA: 135] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
In man, the major function of calcitonin appears to be prevention of excessive or unwanted bone resorption. There is a striking sex difference in circulating levels, with a relative deficiency in women. Calcitonin secretion in young adults is increased by oestrogens and therefore long periods of oestrogen lack, such as after the menopause, may be associated with a more pronounced calcitonin deficiency. This exaggerated deficiency could be an important factor in the pathogenesis of postmenopausal bone loss, especially since the latter may be due to excessive bone resorption. In a study of the effects of oestrogen treatment on circulating levels of calcitonin, parathyroid hormone, and vitamin-D metabolites in postmenopausal women, the most striking change was a sharp rise in plasma-calcitonin. Oestrogens prevent postmenopausal bone loss, and it is suggested that this effect could be mediated, at least in part, through control of calcitonin secretion. Calcitonin may prove effective in the prevention of postmenopausal bone loss, and it is suggested that this effect could be mediated, at least in part, through control of calcitonin secretion. Calcitonin may prove effective in the prevention of postmenopausal bone loss. Its place in the treatment of postmenopausal osteoporosis warrants further evaluation.
Collapse
|
19
|
Pellegrini A, Massidda B, Mascia V, Ionta MT, Lippi MG, Muggiano A, Carboni E, Robustelli della Cuna G, Bernardo G, Strada MR, Pavesi L. Ethinyl estradiol and medroxyprogesterone treatment in advanced breast cancer: a pilot study. Cancer Treat Rep 1981; 65:135-6. [PMID: 7226163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Twenty patients with disseminated breast cancer unresponsive to conventional chemotherapy and chemohormonotherapy were treated with an alternating sequential schedule of ethinyl estradiol and medroxyprogesterone on the basis of correlations between hormones and estrogen and progestin receptors. Of 19 evaluable patients, six underwent partial or complete remission, while five others showed minor responses.
Collapse
|
20
|
Abstract
A placebo-controlled trial has shown that 15 microgram of ethinyl oestradiol is as effective as 25 microgram daily in reducing both menopausal symptoms and the urinary excretion of calcium and hydroxyproline. Norethisterone 5 mg daily also showed a significant reduction in the climacteric symptoms but was less effective than either of the ethinyl oestradiol doses.
Collapse
|
21
|
Abstract
Fifty patients with endometriosis were treated with hormones: 27 with danazol and 23 with Enavid (mestranol 75 micrograms and norethynodrel 5 mg). Side effects were more common and potentially more serious in the group treated with Enavid. Fewer women completed treatment with Enavid and their physical signs showed little improvement. Danazol was better tolerated and the results of treatment, as judged by improvement of symptoms or signs and in future fertility rates, were superior to those recorded in the Enavid treated group. Patients with large endometriotic cysts or severe fibrosis did not benefit from medical treatment. Danazol treatment appeared helpful for women who had mild or moderate endometriotic disease. It may be used alone or as a complimentary treatment after conservative surgical operations.
Collapse
|
22
|
Paterson ME, Sturdee DW, Moore B, Whitehead TP. The effect of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women. Br J Obstet Gynaecol 1980; 87:552-60. [PMID: 6252948 DOI: 10.1111/j.1471-0528.1980.tb05002.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The serum cholesterol and triglyceride concentrations of 84 postmenopausal women both before and after 2, 6 and 12 months therapy with various regimens of hormone therapy were measured. There was little alteration in mean serum cholesterol concentration with cyclical oestrogens but both sequential mestranol and norethisterone and sequential oestradiol valerate and norgestrel significantly reduced the mean serum cholesterol concentration to a level similar to that found in age-matched premenopausal women. There was a small and sometimes significant rise in serum triglyceride concentration with cyclical oestrogens. Sequential mestranol and norethisterone significantly elevated serum triglyceride levels, but sequential oestradiol valerate and norgestrel significantly depressed them. The results suggest that the progestogenic agent norgestrel has an important role to play in reducing both serum cholesterol and triglyceride levels, and that the sequential preparations, by virtue of their greater cholesterol lowering effect, should perhaps be preferred to cyclical oestrogens.
Collapse
|
23
|
Thom MH, Studd JW. Oestrogens and endometrial hyperplasia. Br J Hosp Med (Lond) 1980; 23:506, 508-9, 511-3. [PMID: 6992895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
24
|
|
25
|
Abstract
This study reports some of the effects of oestrogen and progestogen therapy. forty-nine women who had undergone hysterectomy and bilateral salpingo-oophorectomy took part in a double blind crossover study during which they received ethinyl oestradiol 50 micrograms/day, norgestrel 250 micrograms/day, the combination of these substances "Nordiol" and placebo. Somatic complaints were assessed at monthly interviews and weight and blood pressure recorded. The addition of norgestrel to ethinyl oestradiol therapy resulted in less dryness of skin but significantly increased mastalgia and breast size. There were no significant differences between drugs on amount of facial hair, acne, arthralgia, pruritus vulvae, vaginal discharge, vaginal odour, dyspareunia, weight or blood pressure. There was a significant reduction of diastolic blood pressure with the time duration of the study.
Collapse
|
26
|
Quednau D, Garbrecht M, Stolzenbach G, Nowakowski H. [Rebound regression after additional hormonal treatment with ethinyl oestradiol of metastasising carcinoma of the breast in females: frequency and clinical significance (author's transl)]. Dtsch Med Wochenschr 1978; 103:2029-32. [PMID: 729476 DOI: 10.1055/s-0028-1129390] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Rebound regression occurred in 13 of 42 females (30.9% with metastasising carcinoma of the breast in the postmenopausal period in whom additional hormonal treatment with ethinyl oestradiol had brought about a remission. Duration of the rebound response ranged from 3 to 44 months (average 11.2 months; mean 8 months). There was a significantly longer duration of remission (18.7 months compared with 12.0 months; P = 0.01) in patients with than those without a rebound response. There was also a significant correlation between the duration of the preceding remission under additional hormonal treatment and the duration of the subsequent rebound response (P less than 0.01). On the other hand, there was a negative but not significant correlation between the free interval duration which preceded the metastasisation and the duration of the rebound regression.
Collapse
|
27
|
Abstract
Morphological features of testes from four subjects after long-term treatment with ethinyl-estradiol (1--2 mg daily) and from five non-treated patients with prostatic carcinoma were studied by means of light and electron microscopy. The non-treated seminiferous tubules contained spermatagonia, spermatocytes, spermatids, spermatozoa, and Sertoli cells and showed no apparent morphologic abnormalities. On the other hand, the estrogen-treated testicular tissue contained only Sertoli cells and very few spermatogonia within the seminiferous tubules. The nuclei of Sertoli cells occasionally contained two nucleoli. The nucleolar complex was composed of a fine granular spherical body surrounded by a large granular, reticular network. The cytoplasm of the Sertoli cell contained osmiophilic lipid-like bodies. These lipid-like bodies appeared more pronounced in patients treated with higher doses of estrogen, suggesting a diminution of secretion of Sertoli cell hormone. Blebbing from the outer nuclear membrane appeared to have formed numerous vesicles in the cytoplasm. These vesicles usually contained several membrane-bound granular bodies. In the estrogen-treated testes, there was a marked increase in thickness and infolding of the basement membrane. Two unusual patterns of the basement membrane were observed: one appeared to be a reticular anastomosis, the other, an electron-dense trilayer. The morphological picture of seminiferous tubules from the estrogen-treated subjects appeared to correlate well with the suppressed plasma and testicular levels of testesterone, the undetectable circulating gonadotrophins, and the elevated plasma and testicular levels of estradiol-17 beta reported by Rodriguez-Rigau et al. ('77).
Collapse
|
28
|
Stoll BA. Contraceptive steroids and breast cancer. Br Med J 1978; 1:1350-1. [PMID: 647280 PMCID: PMC1604697 DOI: 10.1136/bmj.1.6123.1350-d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
29
|
|
30
|
|
31
|
Abstract
ABSTRACT
The influence of daily oral cyclical oestrogen treatment on the plasma lipid and lipoprotein concentrations was studied in post-menopausal females. Ethinyloestradiol (EOe) 0.05 mg was administered to 20 subjects and oestradiol valerianate (OeV) 2 mg to 19 subjects. The women were investigated twice before medication and 1, 3 and 6 months after the start of treatment.
During EOe therapy the total cholesterol (TC) decreased 10 per cent, high density lipoprotein (HDL)-TC and HDL-phospholipid (PL) increased 30–40 per cent, approximated low density lipoprotein (LDL)-TC decreased 30 per cent and triglyceride (TG) increased 30–40 per cent. In the OeV treated group the HDL-TC and the HDL-PL concentrations showed a mean increase of 10–15 per cent after 6 cycles.
Augmented HDL-TC level and/or decreased LDL-TC level is believed to reduce the risk for the development of atherosclerotic disease. Increased TG concentration probably raises the risk for ischaemic cardiovascular disease. Thus the net effect on the development of ischaemic cardiovascular disease due to the changes of plasma lipids induced by EOe 0.05 mg can at present not be evaluated while the plasma lipid changes observed during OeV 2 mg might hypothetically retard the development of atherosclerosis.
Only 10 per cent of the changes of lipid and lipoprotein concentrations could be explained statistically by their correlations to the simultaneously occurring alterations in the glucose tolerance and the concentrations of insulin and growth hormone. The dissimilar changes in the lipid parameters in the EOe and OeV groups might be explained by the different oestrogenic potency of the drugs and a dose-response relationship of oestrogen treatment on protein and probably lipoprotein synthesis.
Collapse
|
32
|
Abstract
In a prospective trial in 72 postmenopausal women to compare the effects on bone loss of no treatment, treatment with oestrogen, and treatment with calcium the women were followed up for at least two years and examined densitometrically and morphometrically. Women in the untreated control group continued to lose bone during the two years, whereas the oestrogen-treated group lost none. Loss in the calcium-treated group was intermediate. Oestrogen appeared to inhibit endosteal bone resorption and may have stimulated subperiosteal bone apposition.
Collapse
|
33
|
Plesner R. [Estrogens and cancer of the endometrium]. Ugeskr Laeger 1977; 139:1551-2. [PMID: 878060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
34
|
Myhre E. [Comments on the debate concerning estrogen treatment]. Nord Med 1977; 92:166. [PMID: 866112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
35
|
Gambrell RD. Estrogens, progestogens and endometrial cancer. J Reprod Med 1977; 18:301-6. [PMID: 196079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
36
|
Abstract
A technique of incubation of testicular tissue in vitro with radiolabeled precursors was applied in the investigation of the steroid biosynthesis by testes of four young men after long-term, high-dose estrogen treatment. A positive correlation between plasma and testicular steroid levels, and in vitro capacity of the testes to metabolize progesterone was demonstrated. Estrogen administration produced a very significant inhibition of plasma and testicular levels of testosterone. The in vitro synthesis of testosterone from progesterone was very severely impaired; especially 17alpha-hydroxylation of progesterone. 20alpha-hydroxysteroid-dehydrogenase activity was found to be increased after estrogen treatment, both in vivo and in vitro. These findings suggest that testicular 17alpha-hydroxylase activity (and possibly also 17-20 lyase activity) is either under gonadotropin regulation, or is directly suppressed by estrogen. This could result by decreased enzyme synthesis, direct enzyme inhibition or affectation of the cofactors or cytochromes necessary for the enzymatic activity. 20alpha-reduction of C21-steroids would represent an alternative pathway for their catabolism, not regulated by gonadotropin or not affected by estrogen, that would be significant in situations with reduced 17alpha-hydroxylase activity.
Collapse
Key Words
- Age Factors
- Algestone Acetophenide--analysis
- Androgens
- Biology
- Clinical Research
- Contraception
- Contraceptive Agents, Estrogen--administraction and dosage
- Contraceptive Agents, Estrogen--side effects
- Contraceptive Agents, Estrogen--therapeutic use
- Contraceptive Agents, Female--administraction and dosage
- Contraceptive Agents, Female--analysis
- Contraceptive Agents, Female--side effects
- Contraceptive Agents, Female--therapeutic use
- Contraceptive Agents, Progestin--analysis
- Contraceptive Agents--administraction and dosage
- Contraceptive Agents--analysis
- Contraceptive Agents--side effects
- Contraceptive Agents--therapeutic use
- Demographic Factors
- Endocrine System
- Estradiol--analysis
- Estrogens
- Ethinyl Estradiol--administraction and dosage
- Ethinyl Estradiol--side effects
- Ethinyl Estradiol--therapeutic use
- Family Planning
- Follicle Stimulating Hormone--analysis
- Genitalia
- Genitalia, Male
- Gonadotropins
- Gonadotropins, Pituitary
- Histology
- Hormones
- In Vitro
- Luteinizing Hormone--analysis
- Men
- Physiology
- Population
- Population Characteristics
- Progestational Hormones
- Progesterone--analysis
- Reproduction
- Research Methodology
- Spermatogenesis
- Testis
- Testosterone--analysis
- Urogenital System
Collapse
|
37
|
Lauritzen C. [Ovulation inhibitors in climacteric]. Dtsch Med Wochenschr 1977; 102:812-3. [PMID: 194763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
38
|
[Large potential market for estrogens in Scandinavian countries]. Nord Med 1977; 92:148-9. [PMID: 866105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
39
|
Widholm O. [Estrogen treatment only when symptoms are present but complaints should not be neglected]. Nord Med 1977; 92:153. [PMID: 866107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
40
|
[Norwegian guidelines on estrogen treatment]. Nord Med 1977; 92:152. [PMID: 866106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
41
|
|
42
|
[Information or advertising for estrogens]. Nord Med 1977; 92:147-8. [PMID: 866104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
43
|
Furuhjelm M. [Hormone treatment in estrogen deficiency can be as natural as insulin in diabetes]. Nord Med 1977; 92:154-5. [PMID: 866108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
44
|
Dmitriev VN. [Hormontal treatment of pre-tumorous diseases of the testis in rats]. Biull Eksp Biol Med 1977; 83:458-60. [PMID: 857973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Tumours and proliferates of the testes from spermatogenic epithelium were treated with estrogens, and those from the interstitial cells-with androgens and 17-hydrosyprogesterone caproate. Depression of the folliculo-stimulating function of the pituitary body with a simultaneous stimulation of the luteinizing hormones (LH) production under the effect of estrogen led to cessation of teratoma and seminoma growth, and to the resolution of the proliferates. When androgens or 17-hydroxyprogesterone caproate were used, depression of the LH led to cessation of the tumour growth, and to the resolution of proliferion of proliferates from the interstitial cells.
Collapse
|
45
|
Gambrell RD. Postmenopausal bleeding. Clin Obstet Gynaecol 1977; 4:129-43. [PMID: 852206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Key Words
- Age Factors
- Biology
- Bleeding--etiology
- Cancer
- Chlormadinone Acetate
- Contraception
- Contraceptive Agents
- Contraceptive Agents, Estrogen--administraction and dosage
- Contraceptive Agents, Estrogen--therapeutic use
- Contraceptive Agents, Female
- Contraceptive Agents, Female--administraction and dosage
- Contraceptive Agents, Female--therapeutic use
- Contraceptive Agents, Progestin
- Contraceptive Agents, Progestin--administraction and dosage
- Contraceptive Agents, Progestin--therapeutic use
- Contraceptive Agents--administraction and dosage
- Contraceptive Agents--therapeutic use
- Demographic Factors
- Dimethisterone
- Diseases
- Endocrine System
- Endometrial Cancer
- Estrogenic Substances, Conjugated--administraction and dosage
- Estrogenic Substances, Conjugated--therapeutic use
- Estrogens--administraction and dosage
- Estrone--analysis
- Ethinyl Estradiol--administraction and dosage
- Ethinyl Estradiol--therapeutic use
- Examinations And Diagnoses
- Family Planning
- Genitalia
- Genitalia, Female
- Histology
- Hormones
- Medroxyprogesterone Acetate
- Menopause
- Neoplasms
- Norethindrone
- Norgestrel--administraction and dosage
- Norgestrel--therapeutic use
- Oral Contraceptives, Phasic
- Ovary
- Physiology
- Population
- Population Characteristics
- Progestational Hormones
- Progesterone
- Reproduction
- Signs And Symptoms
- Urogenital System
Collapse
|
46
|
Gray LA, Christopherson WM, Hoover RN. Estrogens and endometrial carcinoma. Obstet Gynecol 1977; 49:385-9. [PMID: 193072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A group of 205 women with endometrial carcinoma was matched for age, parity, and year of operation with a group of 205 women who had had hysterectomies for benign disease. In the former group, 32 patients had used conjugated estrogens, while in the latter group 12 had used this hormone, yielding a relative risk of 3.1 (P = 0.0008). Users of other forms of systemic estrogens showed similar elevations in relative risk. Relative risk was related to duration of use, progressing from no evidence of risk among those using the hormone for less than 5 years to an 11.5-fold greater risk for those using it for 10 years or more. Risk was also related to the strength of the medication. The relative risk for users of the 1.25-mg tablets was 12.7 as compared to a two- to fourfold greater risk among users of lesser strength tablets.
Collapse
|
47
|
McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD, Kurland LT. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 1977; 127:572-80. [PMID: 190887 DOI: 10.1016/0002-9378(77)90351-9] [Citation(s) in RCA: 183] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Recent independent case-control studies have indicated that treatment with exogenous estrogen is associated with an increase in the risk of endometrial cancer. This question was studied in Olmsted County, Minnesota, by identifying all cases of endometrial cancer among residents over a 30 year period (1945 through 1974) and by matching four controls to each of the 145 patients. The rate of past exposure to any exogenous estrogen for any duration was about the same for patients as for controls. However, the estimated relative risk of endometrial cancer associated with conjugated estrogen treatment of 6 months or longer was 4.9 (P less than 0.01), and this increased to 7.9 (P less than 0.01) with exposure for 3 years or longer. The risk increased with larger doses (1.25 mg. or more) and continuous administration of conjugated estrogens. The incidence of endometrial carcinoma over the three decades of the study, corrected for an increasing rate of hysterectomy, was constant. Thus to this time, the low rate of use of conjugated estrogens in this region over the past 30 years apparently has not had an appreciable impact on the incidence of endometrial cancer.
Collapse
|
48
|
Rodman MJ. FDA wants patients, M.D.'s warned of estrogen risks. RN 1977; 40:33-4. [PMID: 584014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
49
|
Stamler FW. Disseminated intravascular coagulation induced by progesterone in the pregnant rat. Prevention by estogens. Am J Pathol 1977; 86:603-22. [PMID: 65916 PMCID: PMC2032110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Fatal disseminated intravascular coagulation (DIC) was induced in female rats by administration of progesterone in late pregnacy. This prevented parturition, with intrauterine fetal death 2 to 4 days past term and subsequent retention of dead fetuses. Concomitantly with or closely following the intrauterine death of their litters, a large proportion of pregnant rats died with histologically evident DIC. Administration of cortisone, heparin, or disoumarin did not prevent DIC, and xi-aminocaproic acid, acetylsalicylic acid, or an onion-rich diet tended to increase its incidence. Antibiotic regimens gave variable results, with significant decrease in DIC only with a combination of two wide-spectrum penicillins. Neomycin and polymyxin had little effect on susceptible Sprague-dawley derived rats, but polymxin caused a significant increase in DIC in a resistant strain of hooded rats. Fatal maternal DIC was completely prevented only by use of natural or synthetic estrogens concurrently with progesterone, although this did not alter the sequence of abnormally prolonged pregnacy with intrauterine fetal death and retention of dead fetuses. Potencies of estrogens varied greatly, but all compounds tested prevented DIC at adequate dosage levels. Diethylstilbestrol, the most potent drug tested, was completely protective at 1 mug daily given subcutaneously. beta-Estradiol was the most effective natural estrogen, giving complete protection with a 10-mug daily subcutaneous injection. Estrogens were much more potent by subcutaneous injection than by oral ingestion, and toxic side effects were sometimes noted with higher levels of the latter. For estrogen therapy to be effective, it was necessary to begin its use before the expected onset of DIC, and in no instance was there evidence of reversal of this process after signs of illness were observed.
Collapse
|
50
|
Frölich M, Lachinsky N, Moolenaar AJ. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women. Eur J Endocrinol 1977; 84:333-42. [PMID: 138326 DOI: 10.1530/acta.0.0840333] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women suffering from either idiopathic hirsutism or the polycystic ovary syndrome were determined before and during treatment with cyproterone acetate combined with ethinyl oestradiol. During this treatment the hirsutism decreased markedly. In untreated hirsute women serum dehydroepiandrosterone levels do not differ from those in normal women and do not change during therapy; androstenedione levels are higher than normal and decrease markedly during treatment, and the testosterone levels are elevated compared to normals, with a considerable overlap, and show only a tendency to decrease. There is no correlation between dehydroepiandrosterone and androstenedione levels or between androstenedione and testosterone levels in the serum of untreated hirsute women. After 12-14 months of cyproterone acetate-ethinyl oestradiol therapy a linear correlation is found between dehydroepiandrosterone and androstenedione levels. This can be explained by the relatively higher contribution of the peripheral conversion of dehydroepiandrosterone to androstenedione to the occurrence of lower androstenedione levels. The linear correlation between androstenedione and testosterone after treatment, also found in normal women, indicates the restoration of the role of androstenedione as the major peripheral precursor of testosterone.
Collapse
|